Autopsy report · NCT05394064
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
Cause of deathFunding or business
“The SBT101 program for AMN was terminated for business/strategic reasons, and there were no safety concerns”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 9 months before it stopped.
- 9 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- SwanBio Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- AMN; AMN Gene Mutation; X-ALD
- Interventions
- SBT101 Treatment
- Participants
- 9
- Sites
- 2
- Countries
- Netherlands, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.